

**MINUTES OF THE MEETING OF THE NORTH CUMBRIA AREA PRESCRIBING COMMITTEE
HELD ON THURSDAY 11th OCTOBER 2018 AT 2.00PM
CONFERENCE ROOM, ROSEHILL, CARLISLE**

Present:	Paul Fieldhouse Andrea Loudon Dr Andrea Mulgrew Helen Huck Helena Gregory Helen Seymour Dr Nirmalan Arulanantham Phillip Utting	Clinical Director of Pharmacy, NCUHT Clinical Pharmacy Lead, CCG (Chair) GP Prescribing Lead, Allerdale locality Chief Pharmacist, CPFT (by telephone) Medicines Optimisation Pharmacist, NECS Senior Medicines Optimisation Pharmacist, NECS Clinical Pharmacologist General Physician, NCUHT Professional Secretary Cumbria APC & Senior Medicines Optimisation Technician, NECS
----------	--	--

APOLOGIES FOR ABSENCE

Action

Jan Forlow	Clinical Services Manager Pharmacy, NCUHT
------------	---

DECLARATION OF INTERESTS

None received.

MINUTES OF THE PREVIOUS MEETING

The minutes of the previous meeting held on 16th August 2018 were approved.

ACTION LOG FROM PREVIOUS MEETING (16th August 2018)

Updates were given as follows:

- 05/18 – This action was completed
- 61/18 – This action was completed
- 62/18 – This action was completed
- 66/18 – This action was completed
- 70/18 – This action was completed
- 86/18 – This action was completed
- 89/18 – This action was completed

15/17 Woundcare review

Report currently being collated on the results from the audit sent to both secondary and primary care clinicians. To be reported back at the December 2018 APC meeting.
ONGOING

HH

53/17 NTAG – Paliperidone long acting injection (Xepilon®) and Paliperidone 3 monthly injection (Trevicta®) for schizophrenia – Paliperidone 3 monthly injection (Trevicta®) RECOMMENDED as per its licensed indications. – RED
CPFT awaiting clear guidance until updating on how the SCG’s system will operate when we move across to the North of Tyne APC and Formulary.
ONGOING until decision is made.

60/17 Mesalazine MR prescribing – Noted that this action has been ongoing for some time. With the transition to the NoT formulary Octasa will become first line choice for new patients with current patients on Asacol allowed to stay on this treatment. This decision to be adopted across North Cumbria with the North Of Tyne Consultants to acts as a peer group for the North Cumbria Consultants should they require any advice.
COMPLETED.

72/17 Guidelines for the monitoring of IMD’s – Noted for information. This reference document to be used alongside the Shared Care Guideline updates for North Cumbria as they arise. PF to take forward with NCUHT. ONGOING. PF

04/18 Metolazone and Ranolazine prescribing —The guideline was brought back to the committee with the noted changes from previous meetings. The name of the guideline to be updated to “Prescribing guideline for Metolazone”. The updated document states that primary care will now perform the necessary blood tests for monitoring, due to the Heart Failure Nursing team not having the capacity. Noted that this could not happen in primary care so the nursing team will have to take on this task if the guideline is to be passed. Primary care will be happy to prescribe Metolazone once all the necessary tests have been completed and reviewed by secondary care. PU to inform Mr Ibrahim of the necessary changes. PU
ONGOING

08/18 NG89: Venous thromboembolism in over 16’s: reducing the risk of hospital-acquired DVT or PE – Noted – Clive Graham NCUHT is now leading on this review within NCUHT. New protocol and local guideline to be written. ONGOING JF

18/18 Colomycin nebulisers SCG –BG/JF to feedback to John Atkinson that a patient leaflet is required and also to confirm the patient review arrangements. The sundries needed on the SCG also to be reviewed to see what is exactly is required as these may not be available in primary care. JF
ONGOING

24/18 Transition to North of Tyne APC – Primary care and secondary care formulary review to be done and reviewed by all teams, HG to forward templates to both PF and HH for secondary care. Formulary review meeting to be held on the 14th November to review the differences highlighted by the groups. These can then be brought to the December 18 APC meeting for ratification. ONGOING HG
HH
PF

65/18 Sodium Valproate PREVENT – HH has forwarded the data for North Cumbria to the Mental Health and Learning Disabilities lead within CPFT, this will be shared with the newly appointed Medicines Safety Officer covering both trusts. Item to kept on the agenda until we are aware all processes are suitably in place. ONGOING HH

67/18 Midazolam 10mg/2ml availability at NCUHT – Jo Thomas, Specialist Pharmacist Community Services, CPFT presented the committee with the paper outlining the request to have Midazolam 10mg/2ml injection as stock in certain clinical areas with NCUHT to treat palliative care patients. BG informed the committee that the patient safety panel within NCUHT decided that all Midazolam 10mg/2ml injection be supplied on a named basis only against a prescription chart, no stock to be held on any ward. This was due to a patient safety incident in the past. JF to feedback to the areas / wards where palliative care patients are to be treated to prescribe this drug for these patients earlier in their treatment pathway in the anticipation of its use. ONGOING.

JF

68/18 Insulin passport – HH unable to contact the Diabetic Champion at present, will contact Louise Overend, Consultant Diabetologist, to look at process and for her thoughts in implementation. HG to contact Paul Elwood (NECS MO Pharmacist) regarding further developments of the process. ONGOING.

HH
HG

71/18 FreeStyle Libre supply – AL and HH to work together to aid the supply of FreeStyle Libre from within the trust, with stock being held by the trust for direct supply to patients being one possibility. ONGOING.

AL
HH

90/18 **Recent North of Tyne Formulary decisions**

- **Noted that only the CCG commissioned items to be reviewed, all other NHSE commissioned items to be RED on RAG list.**

Nil this meeting

91/18 **NICE TECHNOLOGY APPRAISALS**

TA538 Dinutuximab beta – Treating neuroblastoma – NHSE commissioned –RED.

TA539 Lutetium (177Lu) oxodotreotide Treating unresectable or metastatic neuroendocrine tumours – NHSE commissioned -RED.

TA540 Pembrolizumab Treating relapsed or refractory classical Hodgkin lymphoma - NHSE commissioned -RED.

TA541 Inotuzumab ozogamicin – Treating relapsed or refractory B-cell acute lymphoblastic leukaemia. - NHSE commissioned –RED.

TA542 Cabozantinib - For untreated advanced renal cell carcinoma. - NHSE commissioned – RED.

TA543 Tofacitinib - Treating active psoriatic arthritis after inadequate response to DMARDs - CCG commissioned –RED – Blueteq form.

PU

92/18 **NICE CLINICAL GUIDELINES**

NG102: Community Pharmacies: Promoting Health and Well Being- Noted – No specific prescribing implications.

NG103: Flu vaccination: Increasing uptake- Noted - No specific prescribing implications.

NG104: Pancreatitis - Noted – to be added to prescription pad.

PU

NG105: Preventing suicide in community and custodial settings – Noted - No specific prescribing implications.

NG106: Chronic heart failure in adults: diagnosis and management– Noted – to be added to prescription pad.

PU

NG107: Renal replacement therapy and conservative management – Noted - No specific prescribing implications.

NG108: Decision making and mental capacity – Noted - No specific prescribing implications.

93/18 **NICE Medicines Optimisation NG5**

Nothing to discuss.

94/18 **CONTRACT MONITORING**

NHSE Contractual Commissioning intentions: Adalimumab – noted for information. COMPLETED.

95/18 **MEDICINES SAFETY**

Noted the new Medicines Safety Officer covering both NCUHT and CPFT is now in post.

CLINICAL MATTERS

96/18 **NTAG- Ferric Maltol – treatment of IDA in patients with IBD** – Recommended as an alternative option in patients with mild to moderate IDA with IBD who have been unable to tolerate at least two oral ferrous salts due to adverts effects. Noted – AMBER – To be added to RAG list. ONGOING.

PU

97/18 **NTAG- Ferric Maltol – treatment of IDA in patients without IBD** – Recommended as an alternative option in patients with mild to moderate IDA who have been unable to tolerate at least two oral ferrous salts due to adverts effects. Noted – AMBER – To be added to RAG list. ONGOING.

PU

98/18 **NTAG – Lycra Garments for the management of cerebral palsy and other neurological and musculoskeletal conditions** – Not recommended – Noted – BLACK – To be added to RAG list. ONGOING.

PU

-
- 99/18 **RDTC report feedback – Wound care** – Noted for information, high use of honey dressings continues while the use of Silver dressings reduces. Overall spend on wound care is reducing. COMPLETED.
- 100/18 **RDTC report feedback – Gastro Intestinal** – Noted for information, low use of laxatives. High cost and volume of alginates continues, this has been an ongoing project within primary care to reduce the volume of Gaviscon Advance prescribed, PF to speak with ENT consultants within NCUHT regarding the current formulary choices. ONGOING. PF
- 101/18 **RDTC report feedback – Antimicrobial** – Noted for information, reduction in prescribing year on year. Unfortunately the Quality Premium target for 2017/18 was not met. Both UTI QP targets were met and exceeded for 2017/18, however further improvement is needed. COMPLETED.
- 102/18 **RDTC report feedback – Bone Metabolism** – Noted for information, Bisphosphonate prescribing volume has decreased but costs have increased due to the spend in Denosumab prescribing. PU to look at Denosumab prescribing to look at increase in patients and spend on exact 2. Noted that Vitamin D prescribing is beginning to reduce in volume. ONGOING. PU

North of Tyne APC Clinical matters for information

- 103/18 **Liothyronine prescribing guideline** – Green + North of Tyne - Noted – to be discussed at the formulary review meeting as to how this will be disseminated to secondary care and how prescribing will be approved. ONGOING. AL
PF
- 104/18 **NoT APC Branded Prescribing guideline** – Approved – Noted – to be added to Prescription Pad. ONGOING. PU
- 105/18 **NoT Catheter Formulary proposal** – Ongoing – Noted at APC the good work and low spend already achieved across North Cumbria.
- 106/18 **NoT Denosumab Information leaflet** – Approved – Noted – Ruth O’Neil (NECS MO Pharmacist) to review current North Cumbria documents and update and remove any duplication. ONGOING. HG
- 107/18 **NoT Antipsychotic leaflet** – Approved with chairs actions to exclude patients in old age taking antipsychotics. Noted also for this document to be adopted by North Cumbria then CPFT would need to be added and also a North Cumbria logo.

OPERATIONAL

- 108/18 **North East & Cumbria Prescribing Forum** - Nothing to report.
- 109/18 **Transition to North of Tyne APC** – PF, HH and AL to take forward the plan to each Board Executive that the three meetings APC and MMC’s will merge to form one local MO implementation meeting.
-

DRUG SAFETY UPDATE

110/18 Drug Safety Update (August 2018) – Noted for information.

111/18 Drug Safety Update (Sept 2018) – Noted for information

112/18 FOR INFORMATION**Minutes received:**

North of Tyne Formulary Sub-committee – Sept 18

North of Tyne Medicines Guideline Group – Sept 18

Prescribing Forum – Aug 18

ANY OTHER BUSINESS

113/18 **Roflumilast RAG rating review** — Mathew Lane, Respiratory Consultant, NCUHT requested the RAG rating of Roflumilast to be in line with the current NoT rating of Green +, APPROVED, current RAG rating to be updated to AMBER. PU

DATE and TIME of next meeting

Thursday 6th December 2018, 2pm at Conference Room, North Cumbria CCG Offices, Rosehill, Carlisle, CA1 2SE
